BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, April 30, 2026
Home » Topics » Financings

Financings
Financings RSS Feed RSS

Cancer immunotherapy illustration

Epitopea closes $14M seed round for tumor antigen discovery

April 25, 2022
By Cormac Sheridan
Epitopea Ltd. raised $13.6 million in seed financing to take forward a new cancer immunotherapy platform based on the identification of a new class of tumor-specific antigens encoded by non-canonical genomic sequences.
Read More

Cambridge Innovations raises £225M fund amid high interest in university spinouts

April 25, 2022
By Nuala Moran
Cambridge Innovation Capital (CIC) has closed its oversubscribed Fund II at £225 million (US$287 million) and is moving from its previous model of open-ended investing to a traditional fixed-term venture capital fund. The money will be dedicated to spinouts from Cambridge University, with CIC investing in series A rounds, but also following on as companies mature and their capital requirements increase.
Read More

Financings for April 25, 2022

April 25, 2022
Med-tech firms raising money in public or private financings, including: Signal 1, Stentit.
Read More

Financings for April 25, 2022

April 25, 2022
Biopharmas raising money in public or private financings, including: Exogene, Forcefield, Healome, Hemostemix, Hillevax, Immunocore, Mitorx, Salarius, Savara, Scynexis, Syncona, Takeda.
Read More

Financings for April 22, 2022

April 22, 2022
Med-tech firms raising money in public or private financings, including: Bioconnection.
Read More

Financings for April 22, 2022

April 22, 2022
Biopharmas raising money in public or private financings, Helix, Noxxon.
Read More

Financings for April 21, 2022

April 21, 2022
Med-tech firms raising money in public or private financings, including: Circle CVI, Endra Life Sciences, Mendel, Nota Labs, Reify Health, Thoma Bravo.
Read More

Financings for April 21, 2022

April 21, 2022
Biopharmas raising money in public or private financings, including: Bristol Myers Squibb, Dermata, Octant, Xinvento.
Read More
Carlsmed Inc.’s Aprevo personalized interbody device

Carlsmed backers provide $30M for personalized spinal implants

April 20, 2022
By Annette Boyle
With an oversubscribed $30 million series B in hand, Carlsmed Inc. is in a good posture to take the next steps in its plan to make its personalized spinal implants central to ending frequent revisions in spine surgery. The company’s Aprevo devices, which are 3D printed for each patient, received FDA breakthrough device designation and 510(k) clearance in late 2020.
Read More

Med-tech financings continue to decline as Q1 records $6.8B

April 20, 2022
By Karen Carey
The amount of money raised by med-tech companies in the early months of 2022 is the lowest amount recorded for a first quarter since 2017. Financings in 2021 were down by 17% over the prior year, which was marked by a flurry of activity and interest in digital technologies and diagnostics with the onset of the COVID-19 pandemic.
Read More
Previous 1 2 … 380 381 382 383 384 385 386 387 388 … 668 669 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 29, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 28, 2026
  • Chinabio 2026 partnering

    Chinese biotechs gain leverage as partners in dealmaking

    BioWorld
    China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
  • Roche identifies new TREM2 agonists

    BioWorld Science
    F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
  • Silhouette of head, brain

    Plasticity, properly parsed, provides psychiatric platform

    BioWorld
    If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing